CA
NZ
UK
AU
IND
US
InfuSystem Holdings, Inc. (NYSE American:INFU), a provider of infusion pumps and related services, has a market capitalisation of about $270 million. The company reported record second-quarter 2026 revenue and has announced a sizeable repurchase programme, so this story concentrates on operating and capital-allocation themes.
iSpecimen Inc. (NASDAQ:ISPC), operator of an online marketplace connecting life-science researchers with biospecimen holders, has a shareholder vote on a reverse stock split open until October 30. The company has a market capitalisation of about $2.85 million. Alongside the vote, it has been raising …
Medpace Holdings, Inc. (NASDAQ:MEDP) has a market value of about $17.31 billion and reports third-quarter 2026 results on October 21 after the market close. The angle is company-specific: the interaction between record bookings, cancellation rates and a year of volatility. Several analysts have recently …
DLH Holdings Corp. (NASDAQ:DLHC), a provider of technology-enabled health and human services to U.S. federal agencies, reported a sharply lower fiscal third quarter on July 29, 2026. Revenue nearly halved, a large tax-related charge pushed the company to a net loss, and management signalled …
enGene Therapeutics Inc. (NASDAQ:ENGN) is a clinical-stage biotechnology company developing detalimogene, a non-viral gene therapy for non-muscle invasive bladder cancer. Investors may be looking ahead to a cluster of fourth-quarter milestones, including updated pivotal data and the start of a Biologics License Application (BLA) …
Evolent Health, Inc. (NYSE:EVH) is in focus as it heads toward its third-quarter report, which the company announced on October 9, 2026 it will release on November 5. The company has a market capitalisation of about $480 million. Management raised its 2026 revenue guidance …
Fortrea Holdings Inc. (NASDAQ:FTRE), a contract research organisation serving drug developers, is attracting differing analyst opinions as it heads toward third-quarter results. It has a market capitalisation near $1.96 billion. Recent rating changes, from a Barclays upgrade to Overweight to a BofA Underperform, suggest …
Merck (NYSE:MRK) presented one-year results on October 12, 2026 for remigromig, its candidate for diabetic macular edema, a swelling of the central retina caused by leaking blood vessels in people with diabetes. Vision improved by 9.1 letters and 8.7 letters in the two remigromig …
First Tracks Biotherapeutics (NASDAQ:TRAX) reported positive Phase 1b data in celiac disease on October 12, 2026, and shares traded between USD 36.78 and USD 38.61 premarket against a USD 31.85 close. That is a gain of about 15.5% to 21.2%, simple arithmetic on published …
Bristol Myers Squibb (NYSE:BMY) announced on October 12, 2026 that admilparant achieved the primary endpoint in idiopathic pulmonary fibrosis at the 60 mg dose but did not reach statistical significance at 120 mg. Idiopathic pulmonary fibrosis is a progressive lung disease in which scar …
Please wait processing your request...